Nucletron has announced that the first Esteya electronic brachytherapy system in the US has been installed at New York's Memorial Sloan-Kettering Cancer Center.
Esteya by Nucletron, an Elekta company, is a new approach for skin cancer treatment that relies on a small, high dose rate (HDR) X-ray source to apply high precision radiotherapy directly to the cancer site.
Elekta Brachytherapy executive vice president John Lapre noted with support from Elekta, Memorial Sloan-Kettering will lead a multicenter clinical study with the goal to further improve skin cancer treatment.
"With its leading role at the forefront of brachytherapy research, the hospital will help advance the quality of patient care and add to the evidence base that caregivers need for their clinical decisions," Lapre added.
Esteya features an efficient workflow, easy patient set-up, and a short, less than three-minute, treatment delivery.
The system's compact design and reduced shielding requirements also make treatment with Esteya highly accessible, enabling clinicians to treat lesions virtually anywhere patients are seen in the clinic.
